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Pancreatic Ductal Adenocarcinoma (PDAC) is a deadly and aggressive disease with a very low survival rate.
This is partly due to the resistance of the disease to currently available treatment options. Herein, we report
for the ﬁrst time the use of a novel polyurethane scaﬀold based PDAC model for screening the short and
relatively long term (1 and 17 days post-treatment) responses of chemotherapy, radiotherapy and their
combination. We show a dose dependent cell viability reduction and apoptosis induction for both
chemotherapy and radiotherapy. Furthermore, we observe a change in the impact of the treatment
depending on the time-frame, especially for radiation for which the PDAC scaﬀolds showed resistance
after 1 day but responded more 17 days post-treatment. This is the ﬁrst study to report a viable PDAC
culture in a scaﬀold for more than 2 months and the ﬁrst to perform long-term (17 days) post-treatment
observations in vitro. This is particularly important as a longer time-frame is much closer to animal
studies and to patient treatment regimes, highlighting that our scaﬀold system has great potential to be
used as an animal free model for screening of PDAC.1. Introduction
Pancreatic Ductal Adenocarcinoma (PDAC) is a deadly
disease with very low prognosis. The 5 year survival rate is
only 5–7% and it has barely improved over the last decades
making it the 5th leading cause of cancer related death in the
UK (https://www.cancerresearchuk.org/health-professional/
cancer-statistics/statistics-by-cancer-type/pancreatic-cancer;
accessed August 2019), 4th in the USA1 and the 7th leading
cause of cancer related death worldwide.2–5 These disheart-
ening statistics have been partly attributed to the disease's
high resistance to current therapeutic regimes (radiotherapy
& chemotherapy). PDAC's high resistance to treatment is
linked to the tumour's complexity.6 More specically, the so-
called tumour microenvironment (TME), which is a cocktailGroup (BioProChem), Department of
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f Chemistry 2019of biochemical, cellular, biomechanical and structural
components has been shown to aﬀect the eﬃciency of treat-
ment delivery to the tumour.4,7–9
Traditionally, PDAC research including treatment screening,
is conducted in (a) 2D in vitro systems10–13 (tissue culture asks
or Petri-plates) or in (b) animals, mainly mice.10,11,14–18Generally,
2D in vitro cultures are responsive to radiotherapy and chemo-
therapy, reproducible and very easy to use.4,13,19 However, the
system is unable to capture key features of the TME such as
structure, stiﬀness, spatial orientation, cell–cell cross talk, cell-
extracellular matrix (ECM) interactions and environmental
gradients.4,20–22 Animal models (mostly murine) are more
accurate/realistic than the 2D in vitro models in capturing
a patient's situation and are currently the most widely used
model for drug and radiotherapy testing at a pre-clinical
level.2,10,14,15,23–27 However, they are expensive, diﬃcult to repro-
duce and complex to use.4,7,21,23,26,28 Additionally, there is
evidence that animal models undergo signicant genetic
changes that diverge from the evolutionary course observed in
human disease, raising concerns about the models' trans-
latability and application for personalised therapies.2
More recently, 3D in vitro models have emerged and are
being developed as low cost, promising alternatives to
animals.7,29–48 However, most studies focus on the development
of the actual 3D model and, to the best of our knowledge, there
are very limited 3D studies on PDAC treatment screening
(chemotherapy and radiotherapy) with most studies conducted
in 3D spheroids (cell aggregates).14,32,34–36,49–52 Generally, theseRSC Adv., 2019, 9, 41649–41663 | 41649
RSC Advances Paperstudies report a higher resistance of PDAC to treatment in 3D
when compared to 2D cultures, a trend which is in closer
alignment with in vivo studies.34,49,52 For example, Longati et al.
(2013) studied the impact of the chemotherapeutic drug Gem-
citabine (GEM, 0–1 mM) on the viability of PDAC spheroids and
observed a higher resistance of the spheroids to the drug, as
compared to a 2D culture. The same study also reported that
chemo-resistance diﬀered amongst diﬀerent cell lines with
PANC-1 showing a higher resistance to GEM in comparison to
BxPC-3 and Capan-1, 7 days aer drug administration.34 Ki
et al., (2014) also observed increased resistance of the PDAC cell
line COLO-357 to GEM within hydrogel based 3D structures as
compared to a 2D culture, 4 days post-treatment.52 More
specically, there was a 6-fold increase in apoptosis in the 2D
culture which was treated with GEM (1 mM) in comparison to
the 3D hydrogels for which there was less than 3-fold apoptosis
induction. Al-Ramadan et al. (2018) also used a spheroid model
for assessment of radiation (0–6 Gy) on the PDAC cell line BON1
and showed a dose dependent increase in cell apoptosis within
the 3D system over a period of 7 days.49
However, even though spheroid type models are easy to
fabricate and responsive to drugs, they cannot mimic robustly
the TME, mainly due to their nature as well as their structural
and spatial organisation.4,20,53,54 More specically: (i) they lack
mechanical stability and mechanical tunability (ii) they cannot
maintain specic spatial cellular orientation (iii) simulation of
mass transfer limitations which realistically occur in a dense
PDAC tissue in vivo are not accurate (iv) the ECM production
cannot be eﬃciently replicated in a spheroid structure, mainly
due to the high variability of the aggregates and the non-
uniform secretion of endogenous ECM (v) due to lack of
porosity and perfusion, they form unrealistically high environ-
mental gradients which do not necessarily occur in vivo,
limiting their accuracy as well as the culture duration, i.e., to
a few days without requiring re-suspension, however the latter
would destroy the formed TME and the formed cell–matrix
interactions. The short culture duration is a key bottleneck for
treatment related studies. More specically, as described above,
most treatment studies in spheroids have been monitored for
a maximum of 7 days,32,34,35,52 which is signicantly shorter in
comparison to patients' treatment time-frame and to animal
models which are usually assessed over a time frame of several
weeks.2,11,14–17,55–57 Furthermore, in vitro models that allow long
term post-treatment monitoring would enable the conduction
of fractionated radiation screening wherein radiotherapeutic
treatment is provided to the patients in serial smaller dosages
over a specic time interval to minimise radiation related side
eﬀects.58–61
We have recently developed a robust polyurethane (PU)
scaﬀold for PDAC (re-)modelling, which overcomes some of the
challenges faced in spheroid systems.7 More specically, due to
the porosity and interconnectivity of our scaﬀolds, pancreatic
cancer cells remain live for more than 4 weeks without need of
resuspension, which to our knowledge is the longest in vitro
culturing period. Furthermore, with appropriate surface modi-
cation of our scaﬀolds with ECM proteins such as bronectin
we observed enhancement of cell proliferation, ECM secretion41650 | RSC Adv., 2019, 9, 41649–41663by the cells as well as the presence of HIF 1a, in our previously
reported work. In this study, we investigate radio-chemo treat-
ment screening in our 3D bioinspired polymer based PDAC
model. It should be stated that this is the rst reported PDAC
treatment screening in a scaﬀold-based system. We performed
chemotherapy and radiotherapy treatment on our scaﬀolds at
week 4 of culture, i.e., the time-point at which we have previ-
ously observed physiological behaviour such as signicant ECM
(collagen-I) secretion, environmental gradients and dense cell
masses. More specically, chemotherapy (with Gemcitabine) as
well as radiotherapy (X-rays) treatments were conducted in our
scaﬀolds and the cell evolution, i.e., viability, apoptosis, cell
mass formation was monitored for 17 days post-treatment and
was spatially visualised with appropriate scaﬀold sectioning,
staining and imaging.2. Materials and methods
2.1 Polymer scaﬀold preparation & surface modication
The scaﬀolds were fabricated via the thermal induced phase
separation method prepared as reported previously.7,62–64
Briey, PU beads (Noveon, Belgium) were dissolved in dioxane
(5% w/v) (99.8% anhydrous pure, Sigma-Aldrich, UK) followed
by quenching at 80 C for 3 h. The solvent was then removed
by freeze drying in a poly-ethylene glycol (PEG) bath at 15 C
under 0.01 mbar vacuum pressure. The scaﬀolds were then cut
into 5  5  5 mm3 cubes and sterilised by exposing them to
70% ethanol (3 h) and UV ray (1 h). As previously reported, the
average pore size of the scaﬀolds was 100–150 mm, the porosity
was 85–90% and the elastic modulus 20  2 kPa (ESI Fig. 1†). It
should be stated that the stiﬀness of the scaﬀolds was similar to
that of PDAC ex vivo tissue.65–67
Thereaer, as previously described, the generated scaﬀolds
were surface modied (adsorption) with bronectin for ECM
mimicry.7 Briey, the scaﬀolds were dipped in Phosphate
Buﬀered Saline (PBS, Sigma-Aldrich, UK) and centrifuged (in
PBS) for 10 min at 2500 rpm. Then, they were transferred to
bronectin solution (25 mg ml1) and centrifuged for 20 min at
2000 rpm, followed by a nal centrifugation step in PBS for
10 min at 1500 rpm to unblock the surface pores of the
scaﬀolds.2.2 3D cell culture
The 3D cell culture was conducted as previously described.7
Briey, the human pancreatic adenocarcinoma cell line PANC-1
(Sigma-Aldrich, UK) was expanded in Dulbecco's modied
Eagle's medium (DMEM) with high glucose (Lonza, UK) sup-
plemented with 10% fetal bovine serum (Fisher Scientic, UK),
1% penicillin/streptomycin (Fisher Scientic, UK) and 2 mM
L-glutamine (Sigma-Aldrich, UK) in a humidied incubator at
37 C with 5% CO2. Cells were passaged regularly on reaching
90% conuency till the required cell density was obtained. For
all experimental conditions, 0.5  106 cells (re-suspended in 30
ml of cell culture media) were seeded in each scaﬀold and the
scaﬀolds were placed in 24 well plates. Immediately aer
seeding, the scaﬀolds were placed in the incubator to facilitateThis journal is © The Royal Society of Chemistry 2019
Paper RSC Advancescell attachment for 1 hour. Thereaer, 1.5 ml of cell culture
media was added to each well and incubation took place in
a humidied incubator at 37 C with 5% CO2 for the entire
duration of the experiment (2 months). The cell culture medium
was changed every two days. Furthermore, to avoid cell con-
uency at the bottom of the wells due to cell egress from the
scaﬀolds, all scaﬀolds were placed in a new well plate once
a week.2.3 Treatment protocol in the 3D scaﬀolds
At week 4 of culture the scaﬀolds were exposed to diﬀerent
treatment regimes, i.e., chemotherapy, radiotherapy or
a combination. This time point was selected as we have
observed and previously reported that, on week 4 of culture, the
pancreatic cancer cells form high cell masses within the scaf-
folds (ESI Fig. 2†) along with secretion of collagen-I and pres-
ence of HIF 1a in some areas within our scaﬀold. Furthermore,
at this stage of culture the cells within the scaﬀold are highly
proliferative. Overall, at this point of the culture the cells exhibit
physiological features, therefore, that time point is ideal for the
conduction of treatment screening.7
2.3.1 Chemotherapy treatment. For the chemotherapy
treatment of the scaﬀolds, the chemotherapeutic agent gemci-
tabine (GEM, Sigma-Aldrich, UK) was selected. GEM is used
extensively for treatment of pancreatic cancer both in
vivo12,14,56,59,68–74 and in vitro12,14,19,34,35,51,52,75 studies.
For the conduction of chemotherapy, GEM at concentrations
of 10, 50 and 100 mMwas added to the culture for 1 feeding cycle
(48 h) and removed thereaer.76 These concentrations were
selected based on dosages used in previously published PDAC in
vitro studies.10,33,35,68,72 Thereaer, the scaﬀolds were charac-
terised 24 h and 17 days aer treatment with sectioning,
staining and advanced imaging. These time points were
selected to study the immediate responses to GEM33,34,36 and to
mimic in vivo treatment regimes.14,77
2.3.2 Radiotherapy treatment. Radiotherapy treatment on
the scaﬀolds was performed with a clinical 250 kV X-ray irra-
diator, Xstrahl 300 (Xstrahl, Camberley, UK) at the Royal Surrey
County Hospital NHS Foundation Trust. More specically, at
the end of week 4 of culture, the scaﬀolds were irradiated with
radiation doses of 2, 6 and 8 Gy, selected based on established
in vitro experimental protocols49,50 and in vivo regimes followed
in mouse model.55 A square eld applicator of 15  15 cm was
placed 3 cm above the plate surface which was placed on an
epoxy resin water equivalent phantom in order to ensure
a uniform radiation eld with known radiation scattering
conditions. It should be stated that control scaﬀolds were used
to account for the potential cell stress during transportation
from the tissue culture lab to the hospital facilities. Thereaer,
the scaﬀolds were monitored and fully characterised (24 hours
and 17 days post-treatment), as described in Section 2.3.1
above.
2.3.3 Combination of chemotherapy and radiotherapy.
Combinatorial treatment protocols, i.e., chemotherapy and
radiotherapy, for PDAC have been studied in some cases. More
specically, 2D in vitro and in vivo murine model studies haveThis journal is © The Royal Society of Chemistry 2019highlighted the positive eﬀects of combining chemotherapy
and radiation as a treatment protocol for PDAC.78,79 However,
clinical studies report contradictory results for such combina-
torial treatment regimens involving chemotherapeutic agents
and radiation in relation to their eﬃcacy in comparison to
chemotherapy alone.69,80–82 Hence, we also studied the eﬀect of
a chemoradiotherapy treatment regime on our scaﬀold-based
model. More specically, for this combined treatment 10 mM
GEM and a 6 Gy radiation dose were used. These levels of
treatment were selected as we observed that they were harsh
enough to induce cell death but not total death and conse-
quently their combination would allow the evaluation of
potential synergies between the two treatments. The scaﬀolds
were exposed to GEM (10 mM) for 48 h followed by radiation
(6 Gy). Post treatment monitoring was carried out as described
in Sections 2.3.1 and 2.3.2 above. Appropriate experimental
controls were used in all cases, as described in Sections 2.3.1 &
2.3.2.
2.4 Spatial evaluation of live and dead cells in the scaﬀolds
via confocal imaging
To visualise the spatial distribution of live and dead cells pre-
and post-treatment, scaﬀolds were collected, sectioned, stained
and further imaged. More specically, scaﬀolds were collected
at appropriate time points, snap frozen in liquid nitrogen for
15 min and then preserved at 80 C. The method of scaﬀold
preservation has been widely used in the eld of tissue engi-
neering and is known to aid in preservation without harming
the cells.83–85 For live/dead cell analysis a Live/Dead Viability/
Cytotoxicity kit was used7 (Molecular Probes, Thermo Scien-
tic, UK). Prior to analysis scaﬀolds were sectioned and washed
twice with PBS, stained with 2 mM of Calcein-AM (4 mM stock)
and 4 mM of Ethidium Homodimer (2 mM stock) and were
incubated at 37 C for 1 h. The solution was then removed, and
the samples were washed twice in PBS followed by imaging
using a Nikon Ti-Eclipse inverted confocal microscope (Nikon
Instruments, Europe).
2.5 Spatial evaluation of apoptotic cells (caspase 3/7 activity)
in the scaﬀolds via confocal imaging
The caspase 3/7 activity was visualised and quantied in situ to
assess the induction of cellular apoptosis aer diﬀerent treat-
ments. Scaﬀolds were collected at diﬀerent time points and
processed as described above (Section 2.4). Thereaer, the
scaﬀolds were incubated in culture medium containing (i) the
Cell Event Caspase-3/7 green detection reagent (Fisher Scien-
tic, UK) and (ii) DAPI (Fisher Scientic, UK) for 1 h at 37 C.
The presence of caspase 3/7 positive cells (green) was immedi-
ately evaluated with a Nikon Ti-Eclipse inverted confocal
microscope (Nikon Instruments, Europe).
2.6 Confocal laser scanning microscopy (CLSM) imaging
Immunouorescent samples (prepared as described in Sections
2.4 & 2.5 above) were imaged on a Nikon Ti-Eclipse inverted
confocal microscope (Nikon Instruments, Europe) and pro-
cessed with the NIS-Elements soware, using 405, 488 andRSC Adv., 2019, 9, 41649–41663 | 41651
RSC Advances Paper561 nm lasers for DAPI (blue), green uorescence (calcein and
caspase 3/7) and Ethidium Homodimer (red) staining respec-
tively. Confocal images were captured using a 10 objective and
a 5–10 mm Z-stack distance. The same acquisition conditions
were used for the positive controls. Multiple scaﬀolds as well as
multiple areas and sections per scaﬀold were imaged to ensure
reproducibility. Representative images are presented in this
manuscript.
2.7 Image analysis
For the quantitative evaluation of (i) the live (green) and dead
(red) population as well as (ii) the caspase positive/apoptotic
(green) and non-apoptotic (blue) population of each image,
the percentage of green vs. red (live/dead) or green vs. blue
(caspase positive/caspase negative) areas of each image were
calculated using Image J® soware (Wayne Rasband, NIH,
Bethesda, MD, USA). The particle analyser macro (Image J®,
Wayne Rasband, NIH, Bethesda, MD, USA) was used in each
individual channel (green or read for live/dead and green or
blue for the caspase 3/7 respectively).
This approach is hugely benecial in 3D scaﬀolds as it
provides a quantitative indication of the live/dead and apoptotic/
non apoptotic cell distribution within the various scaﬀold areas
for diﬀerent treatment conditions.41,86 The latter is particularly
important as we have seen that metabolic activity dependent
assays like the MTT assay and Alamar Blue assay are aﬀected by
various parameters including cytotoxic agents and are not
sensitive enough to identify diﬀerences in cell population within
the scaﬀolds, especially for very high cell numbers.87–89 In
contrast, imaging is muchmore representative and reproducible.
As described above, multiple scaﬀold sections (at least 3) from at
least 3 replicate scaﬀolds were analysed for each condition to
ensure reproducibility of the results.
2.8 Statistical analysis
Statistical analysis was performed for at least 3 independent
experiments with at least 3 replicates per time-point (N $ 3,
n $ 3). Analysis of Variance (one-way ANOVA) followed by the
Tukey's multiple comparison test using the Graph Pad Prism®
soware (version 6.00 for Windows) in order to nd statistically
signicant diﬀerences between data (p < 0.05) was carried out.
Untreated samples were considered as control in all cases. The
error bars in the graphs represent standard error of mean.
3. Results
3.1 Chemotherapy assessment in the 3D scaﬀolds
As mentioned previously, Gemcitabine (GEM), a standard
chemotherapeutic agent against PDAC73–75,90,91 was introduced
to the culture medium surrounding the scaﬀolds at week 4 of
culture and at diﬀerent concentrations, i.e. 10, 50 and 100 mM,
for 1 feeding cycle, i.e. 48 h. Thereaer, the medium containing
the drug was removed and replaced with fresh medium. The
scaﬀold culture was further maintained and monitored for 17
days post-treatment. In order to assess the short and long term
responses to GEM, the scaﬀolds were assessed 24 h and 17 days41652 | RSC Adv., 2019, 9, 41649–41663post-treatment. Staining, sectioning and imaging of the scaf-
folds at those diﬀerent time points (as described in Sections
2.4–2.7) with CLSM enabled the spatial assessment and quan-
tication of the impact of GEM on the cell viability and
apoptosis induction in the scaﬀolds (Fig. 1 and 2). More
specically, Fig. 1A shows representative live areas on scaﬀold
sections for various concentrations of GEM while Fig. 1B shows
the distribution of apoptotic areas on representative scaﬀold
sections, 24 h post treatment. Fig. 1C and D show the equivalent
quantications (performed as described in Section 2.7). A day
aer treatment, a drug dose dependent decrease in cell viability
was observed within the scaﬀolds (Fig. 1A and C). From
a quantitative point of view this reduction was statistically
signicant only for 50 mM and 100 mM GEM, i.e., the higher
doses used. It should be stated that, for the higher doses of
GEM, there was a signicantly lower number of cells in the
scaﬀolds, due to the detachment of severely damaged/dead
cells92 from the polymeric matrix. In terms of apoptosis, an
increase of apoptosis with higher GEM concentrations was
observed, as evaluated with caspase 3/7 activity (Fig. 1B and D).
Furthermore, a high number of apoptotic cells was observed
even for low concentrations of GEM (Fig. 1D), indicating that
the drug had an immediate action and had impacted/stressed
the cells even at low concentrations. More specically, for 10
and 50 mM GEM a mixed cell population with both apoptotic
and non-apoptotic cells was observed while for 100 mM GEM
almost all the population was apoptotic. Furthermore, as can be
seen in Fig. 1D, the quantitative diﬀerence of the apoptotic
induction was statistically signicant for all drug
concentrations.
The cell death and apoptosis levels were also assessed 17
days post treatment to evaluate the long-term response to the
drug in the scaﬀolds (Fig. 2). It should be stated that this is the
rst time that such an extended culturing period has been re-
ported in vitro. Interestingly the control remained very high in
viability (Fig. 2A) and low in apoptotic levels (Fig. 2C) aer
almost 2 months in culture. The live-dead staining (Fig. 2A) and
quantication (Fig. 2C) showed a signicant decrease in green/
live image areas of the scaﬀold sections for all tested concen-
tration of GEM as compared to untreated scaﬀolds in contrast
to the 24 h post-treatment response which was signicant only
for the higher drug doses (50 and 100 mM GEM). The apoptosis
induction was signicantly higher as compared to the untreated
scaﬀolds for all drug concentrations under study with no
signicant diﬀerences for the two higher drug doses, for which
the majority of the population was apoptotic (Fig. 2B and D).
Overall, these results indicate the importance of having
a system that enables long term post-treatment drug response
monitoring.3.2 Radiotherapy assessment in the 3D scaﬀolds
Application of radiotherapy (X-rays) in the 3D scaﬀolds was
carried out at the Royal Surrey County Hospital, NHS Founda-
tion Trust (see Section 2.3.2). More specically, the scaﬀolds
were exposed to one-oﬀ radiation treatment for doses of 2 Gy, 6
Gy and 8 Gy. As described for the chemotherapy experiments, toThis journal is © The Royal Society of Chemistry 2019
Fig. 1 Eﬀect of GEM in the scaﬀolds 24 h post-treatment. (A) Representative images for live-dead staining. (B) Representative image for
apoptosis (caspase 3/7) staining. (C) Image analysis based quantiﬁcation of live (green) image areas for diﬀerent GEM concentrations. (D) Image
analysis based quantiﬁcation of apoptotic areas on scaﬀold sections for various GEM concentrations. Multiple images ($3) andmultiple scaﬀolds
($3) were analysed the mean values were used here.
Paper RSC Advancesassess the short and relatively long term responses to radiation,
the scaﬀolds were analysed 24 h and 17 days post-treatment.
More specically, sectioning, staining and imaging of the
scaﬀolds (as described in Sections 2.4–2.7) with CLSM enabled
the spatial assessment and quantication of the radiation
responses on the cell viability and apoptosis induction 24 h
(Fig. 3) and 17 days (Fig. 4) post-treatment.
As can be seen on Fig. 3A and C, 24 h aer radiation treat-
ment, there was no signicant impact from low dosages of
radiation, i.e., 2 Gy and 6 Gy, on the viability while a signicant
decrease in viability was observed for the highest radiation
dose, i.e., 8 Gy. Additionally, much more live cells were retained
in the scaﬀolds aer radiation treatment (Fig. 3A) as compared
to the GEM treated samples (Fig. 1A). Similarly, the apoptosisThis journal is © The Royal Society of Chemistry 2019(caspase 3/7 activity) assessment showed that only exposure to 8
Gy resulted in a signicant increase in cell apoptosis within the
scaﬀolds (Fig. 3B and D), in contrast to the eﬀect of GEM, which
led to high cell apoptosis even for the lowest drug concentration
(Fig. 1A). Overall, these ndings indicate that the immediate
response (24 h post-treatment) to 10 mM GEM on the scaﬀolds
was much higher than that of 2 Gy radiotherapy treatment,
resulting in higher death and higher apoptosis.
However, the impact of radiation on the viability and
apoptosis induction in the scaﬀolds was much more signicant
17 days post-treatment (Fig. 4A and C). More specically, scaf-
folds treated with radiation showed a dose dependent viability
reduction. Moreover, scaﬀolds treated with 8 Gy radiation, were
virtually empty suggesting extreme lethal dosage, the impact ofRSC Adv., 2019, 9, 41649–41663 | 41653
Fig. 2 Eﬀect of GEM in the scaﬀolds 17 days post-treatment. (A) Representative images for live-dead staining. (B) Representative image for
apoptosis (caspase 3/7) staining. (C) Image analysis based quantiﬁcation of live (green) image areas for diﬀerent GEM concentrations. (D) Image
analysis based quantiﬁcation of apoptotic areas on scaﬀold sections for various GEM concentrations. Multiple images ($3) andmultiple scaﬀolds
($3) were analysed the mean values were used here.
RSC Advances Paperwhich was realistically captured 17 days aer treatment. In
terms of apoptosis, a signicant increase was observed for all
treatment doses as compared to untreated scaﬀolds (Fig. 4B and
D). This data suggests that unlike chemotherapy, the response
to radiation on the PDAC scaﬀolds is not immediate but can be
seen more clearly long-term; therefore, having a platform that
allows long-term treatment monitoring can be very informative.3.3 Combined chemotherapy and radiotherapy treatment in
the scaﬀolds
Further to independent chemotherapy and radiotherapy
treatments, a chemo-radiotherapy combinatorial treatment
regime was tested in our 3D scaﬀolds. More specically,
a combination of 10 mM GEM and 6 Gy radiation was applied.41654 | RSC Adv., 2019, 9, 41649–41663These levels of treatment were selected based on our ndings
from the individual treatments, i.e., they were found to be
independently eﬃcient enough to induce cell death but not
total death, therefore, their combination would allow the
evaluation of potential synergies (Fig. 1–4). Indeed, as
observed in Fig. 5 and 6, both 24 h and 17 days post treatment,
the use of a chemo-radiotherapy combination showed
a signicantly higher cell death and apoptosis induction as
compared to the independent treatments. This highlights the
potential synergy of the diﬀerent treatment methods in
enhancing cell death and apoptosis induction both short and
long term.This journal is © The Royal Society of Chemistry 2019
Fig. 3 Eﬀect of radiotherapy in the scaﬀolds 24 h post-treatment. (A) Representative images for live-dead staining. (B) Representative image for
apoptosis (caspase 3/7) staining. (C) Image analysis based quantiﬁcation of live (green) image areas for diﬀerent dosage of radiation. (D) Image
analysis based quantiﬁcation of apoptotic areas cells on scaﬀold sections for various dosages of radiation. Multiple images ($3) and multiple
scaﬀolds ($3) were analysed the mean values were used here.
Paper RSC Advances4. Discussion
In the current work, treatment screening, i.e., chemotherapy,
radiotherapy and a combination of the two were performed, for
the rst time, in a novel polymer scaﬀold based PDAC model.
We have developed and recently published a PU based highly
porous polymeric scaﬀold, decorated with ECMmatrix features,
i.e., bronectin, for PDAC re-modelling. Due to the porosity and
pore interconnectivity within the scaﬀolds, we have recently
reported that pancreatic cancer cell lines remain alive for more
than a month in culture, without the requirement of cell re-
suspension, which is the longest reported culturing period in
vitro. On week 4 of culture, the cells in the scaﬀold developed
some in vivo like features such as the formation of dense cellThis journal is © The Royal Society of Chemistry 2019masses, beginning of the secretion of ECM protein (collagen I),
and some degree of oxidative stress. Furthermore, majority of
the population was proliferative throughout the whole scaﬀold
aer a month in culture. It should be stated that a similar
proliferation distribution within the tumour has been recently
reported in a PDAC orthotopic mice model (Fig. 7A) Therefore,
in this work we performed treatment screening on week 4
culture of PANC-1 cells in the scaﬀolds, as at this time point the
scaﬀold had signicant in vivo like features. More specically,
the scaﬀolds were treated with chemotherapy (GEM), radio-
therapy (X-rays) and a combination of both. Sectioning, staining
and image analysis of multiple scaﬀolds pre and post-treatment
enabled us to spatially map the viable as well as the apoptotic
population for various conditions both short-term, i.e., 24 hRSC Adv., 2019, 9, 41649–41663 | 41655
Fig. 4 Eﬀect of radiotherapy in the scaﬀolds 17 days post-treatment. (A) Representative images for live-dead staining. (B) Representative image
for apoptosis (caspase 3/7) staining. (C) Image analysis based quantiﬁcation of live (green) image areas for diﬀerent dosage of radiation. (D) Image
analysis based quantiﬁcation of apoptotic areas cells on scaﬀold sections for various dosages of radiation. Multiple images ($3) and multiple
scaﬀolds ($3) were analysed the mean values were used here.
RSC Advances Paperpost-treatment (Fig. 1, 3, and 5), and relatively long term, i.e., 17
days post-treatment (Fig. 2, 4, and 6). To the best of our
knowledge, we are the rst to report in vitro such long post-
treatment observations/monitoring, similar to the time-frame
employed in animal studies2,12,14,15,17,23,55 and in patients.56,69,81
In contrast, most treatment screening studies in in vitromodels
to date have post-treatment assessment time-frame of
a maximum of one week and they are mainly conducted for
chemotherapy.33–364.1 Chemotherapy treatment in the scaﬀolds
As previously mentioned, (see Sections 2.3.1 and 3.1), the
chemotherapeutic agent Gemcitabine (GEM) was used for41656 | RSC Adv., 2019, 9, 41649–41663conducting chemotherapy treatment on our scaﬀolds. GEM is
a drug that is used for PDAC treatment clinically56,69 as well as in
various in vivo12,14,15,18 and in vitro studies.12,19,33,34,72,75,91
Most in vitro studies are in 2D systems and very few in 3D,
mostly spheroid typemodels. Furthermore, most in vitro studies
(2D and 3D) are relatively short term and hence do not capture
the long-term response to various drugs, unlike in vivo studies
that are much longer, i.e., several weeks, both for animals and
patients. For example, Lee et al.33 (2018), studied the impact of
several drugs (gemcitabine, paclitaxel and oxaliplatin) on the
viability of PANC-1 cells in a 3D spheroid system and showed
a dose dependent decrease in cell viability for most of the drugs,
72 h post treatment. Longati et al., (2013) treated PANC-1 andThis journal is © The Royal Society of Chemistry 2019
Fig. 5 Eﬀect of combinatorial treatment (GEM + radiation) approach 24 h post treatment. (A and B) Representative image of live-dead staining
and caspase 3/7 staining on scaﬀold sections respectively. (C) Image analysis based quantiﬁcation of percentage of live/green image area. (D)
Image analysis based quantiﬁcation of apoptotic area. Multiple images ($3) andmultiple scaﬀolds ($3) were analysed themean values were used
here.
Paper RSC AdvancesBxPC-3 cells in 2D as well as 3D spheroids with GEM and per-
formed post treatment analysis aer 7 days. Cells in 3D were
more chemo-resistant than in the 2D culture.34 Lazzari et al.,
(2018) monitored the viability of GEM treated pancreatic cancer
spheroids for 72 hours and reported that at 10 and 50 mM of
GEM the tumour spheroid viability loss was 20% and 30%
respectively, highlighting the dose dependent nature of GEM's
action on PDAC.32 Ki et al., investigated the eﬃciency of 1 mM of
GEM through monitoring of apoptosis (caspase 3/7 expression)
in a hydrogel based pancreatic cancer model. The caspase 3/7
activation was 6-fold higher as compared to the untreated
hydrogels 4 days aer treatment.52 However, to the best of our
knowledge scaﬀold based in vitromodels of PDAC have not been
used for treatment studies to date.This journal is © The Royal Society of Chemistry 2019In contrast to reported 3D in vitro studies which last
a maximum of one week post-treatment, animal studies and
clinical trials are carried out for a more extended time period,
i.e., several weeks highlighting a key drawback for most in vitro
3D models. For example, Awasthi et al., (2019) studied ortho-
topic tumours of PDAC cell lines in mice for a total of 4 weeks
which included 2 weeks post treatment observation.14 Liu et al.,
(2010) studied the eﬀect (growth inhibition and gene expression
of apoptotic related pathways) of the drug Matrine on PDAC
xenogras in a mouse model for about 3 weeks post-treat-
ment.17 The longest reported mouse study was carried out by
Krzykawska-Serda et al., in 2018 wherein they carried out anal-
ysis 4 weeks post treatment with the total experiment running
for 10–12 weeks.77 In a similar fashion, clinical trials are alsoRSC Adv., 2019, 9, 41649–41663 | 41657
Fig. 6 Eﬀect of combinatorial treatment (GEM+ radiation) approach 17 days post treatment. (A and B) Representative image of live-dead staining
and caspase 3/7 staining on scaﬀold sections respectively. (C) Image analysis based quantiﬁcation of percentage of live/green image area. (D)
Image analysis based quantiﬁcation of apoptotic area. Multiple images ($3) andmultiple scaﬀolds ($3) were analysed themean values were used
here.
RSC Advances Papercarried out for a longer time frame with drug doses distributed
over months to avoid excessive toxicity.16,56,58,69
In our work, we studied the eﬀect of 10, 50 and 100 mM of
GEM on the viability and apoptosis induction of pancreatic
cancer cells in polymer based scaﬀolds short term (24 hours
post treatment) and relatively long term (17 days post treat-
ment), the latter being similar to the post-treatment pattern
followed in animal studies.2,12,14,15,17,23,55 Due to the high cell
death at 100 mM GEM, i.e., less than 50% viability was observed
24 h post-treatment (Fig. 1), we did not test higher drug
concentrations. Similar to other reported in vitro studies for
spheroids/hydrogels, the eﬀect of GEM on the viability and
apoptosis induction (caspase 3/7 activation) was generally dose
and/or day dependent. More specically, 24 h post-treatment,41658 | RSC Adv., 2019, 9, 41649–41663the viability of the scaﬀolds did not signicantly decrease as
compared to the control for 10 mM of GEM but higher death
(including emptier scaﬀold sections due to detachment of dead
cells from the scaﬀolds) were observed for 50 and 100 mM
(Fig. 1A and C) while the induction of apoptosis followed amore
clear drug dose-dependent trend (Fig. 1B and D). In contrast, 17
days post treatment, an impact of the drug on the viability was
observed for all concentrations under study in a clear dose
dependent manner (Fig. 2). We also observed signicantly
higher loss of cell viability for 100 mMGEM in comparison to 10
mM and 50 mM GEM highlighting further dose dependence for
the drug (Fig. 2A and C). In terms of apoptosis induction, there
was a signicant induction of apoptosis for all drug concen-
trations under study as compared to the untreated scaﬀold (theThis journal is © The Royal Society of Chemistry 2019
Fig. 7 (A) Representative immunoﬂuorescent staining for cell distribution (DAPI) and proliferation (Ki-67) (i) on our 3D scaﬀold based pancreatic
cancer model (adaptedwith permission from Totti et al., 2018)7 and (ii) on anmousemodel (adaptedwith permission from Erstad et al., 2018).2 (B)
Apoptosis expression (i) on the 3D pancreatic cancer model 17 days post treatment for 50 mM (left) and 100 mM (right) of GEM and (ii) on a mouse
model 18 days post treatment for similar doses of the drug Matrine (adapted with permission from Liu et al., 2010).17
Paper RSC Advancesapoptosis level of which remained very low even aer 2 months
in culture). The apoptosis induction was signicantly higher for
higher drug doses (50 mM and 100 mMGEM) as compared to the
low drug dose used (10 mM) (Fig. 2B and C). As mentioned
previously, we are the rst to perform long-term post-treatment
monitoring in vitro, therefore, there is no existing literature to
compare our results in that length of time-frame. However, the
cell death and apoptotic patterns we observe are similar to
PDAC mouse studies (Fig. 7B). More specically, as can be seen
in Fig. 7B(ii), approximately 3 weeks post-treatment monitoring
of apoptosis in mice resulted in a similar dose dependent
increase in apoptotic induction17 to the one observed in our
system, highlighting the great potential of our scaﬀold for the
performance of chemotherapy screening in a more realistic
time regime which is closer to the animal23,77,93 and human56–58,69
treatment situation.4.2 Radiotherapy treatment in the scaﬀolds
Generally, there are limited radiotherapy studies in PDAC, even
though it is a common treatment option, especially for patients
with advanced disease.58,69 Tuli et al., studied the cell viability
reduction and the DNA damage of PDAC in response to various
doses of radiation (0–10 Gy) in a 2D mono-layer culture system
and reported a radiation dose dependent decrease in cell
viability along with instant DNA damage for the highest radia-
tion dosage.55 Giagkousiklidis et al., (2007) also reported in a 2D
system that XIAP inhibition increased the sensitivity of PDAC
cell lines to radiation (10 Gy, 20 Gy) 96 h post treatment.94 To theThis journal is © The Royal Society of Chemistry 2019best of our knowledge, there are only two studies that explore
the radiation eﬃcacy utilizing 3D pancreatic cancer models in
the form of spheroids and for a relatively short time duration,
i.e. a maximum of 7 days.49,50 Hehlgans et al. (2009) used a 3D
spheroid model to study the response of Caveolin-1 (membrane
protein) knockdown on the PDAC MiaPaCa2 cell line response
to radiation (0–6 Gy)50 and reported an increased sensitivity to
radiation of the Caveolin-1 knockdown in 3D as compared to
the wildtype. Furthermore, a 12 days study on tumour spheroids
by Al-Ramadan et al. (2018), showed that spheroids of the PDAC
cell line BON1 exhibited a dose dependent (0–6 Gy) increase in
the apoptotic maker caspase 7 days post treatment.49 Small
animal models (mice) have also been used by diﬀerent groups
to study the eﬀects of radiation on PDAC.55,95,96 For example,
Tuli et al., (2014) reported that a mouse model developed with
orthotopic implant of PDAC cells, was able to survive for up to
39 days post treatment (5 Gy, single fraction radiation).
Based on the radiation dosages reported,49,50,55 we performed
radiation with X-rays for doses of 2, 6 and 8 Gy (see Sections
2.3.2 and 3.2). Similarly to published data for 2D,55 3D in vitro50
and in vivo55 systems, we generally observed a dose/time
dependent trend on cell death and apoptotic induction (cas-
pase 3/7 expression) throughout the assessment period (24 h
and 17 days post-treatment) (Fig. 3 and 4). More specically,
a signicant increase in apoptosis and death 24 h post-
treatment was only observed at 8 Gy (Fig. 3), in contrast to
GEM, which resulted in a signicant increase in apoptosis 24 h
post-treatment for all drug doses under study (Fig. 1). The
enhanced eﬃciency of chemotherapy compared to radiotherapyRSC Adv., 2019, 9, 41649–41663 | 41659
RSC Advances Paperfor pancreatic cancer has also been reported by European
clinical trials for pancreatic cancer. Namely, the European Study
Group for Pancreatic Cancer (ESPAC) assessed the eﬃciency of
systemic chemotherapy and radiation for pancreatic cancer
patients and reported the benet of chemotherapy in compar-
ison to radiotherapy.82,97
In our work, 17 days post-treatment, a signicantly higher
impact on the viability reduction and apoptosis induction was
observed for all radiation doses under study, as compared to the
untreated scaﬀolds (Fig. 4). The increased radio-resistance we
observe 24 h post-treatment is in accordance with in vitro
studies in other systems for similar post-treatment time
frames.49,50 However, our long post-treatment observations
clearly show that radiation does inuence the PDAC scaﬀolds,
but not immediately.
Overall, we are the rst to report long-term radiation
responses in a novel polymer based scaﬀolding system. Having
a low-cost robust screening system for PDAC radiotherapy
screening is particularly important not only because radiation
on PDAC has been understudied, but furthermore, due to the
limited availability of preclinical (animal) facilities for standard
radiotherapy screening and the complete lack of animal facili-
ties to screen novel radiotherapy regimes. More specically,
novel radiotherapy regimes, e.g., with protons or in the presence
of high magnetic elds as with MRI-linear accelerators,98–100 are
generally understudied and, considering the output of the
ESPAC trial and others for PDAC (see above), novel radiation
approaches could be more eﬃcient. Indeed, there are some
clinical trials on proton therapy which show promising results
for PDAC.101–104Our platform could help accelerate those studies
in a reproducible in vitro environment which mimics closer the
in vivo situation, as shown in Fig. 7.4.3 Assessment of combination of chemotherapy and
radiotherapy in the scaﬀolds
As previously mentioned, in recent years, clinical trials are
focusing on the potential synergistic eﬀect of radiotherapy and
chemotherapy but with contradictory results.82,97,105,106 Elada-
wei et al., (2017) have shown in their clinical trial that
a combined chemo-radiotherapy is more eﬀective than
chemotherapy alone on patients who have undergone surgery,
although some level of toxicity was observed.105 In contrast,
Neoptolemos et al., (2001) reported in their clinical trial that
chemo-radiotherapy showed no added benet for patients in
comparison to chemotherapy alone.82 To the best of our
knowledge, very limited studies have been carried out in vitro
to understand the response of chemoradiotherapy on
PDAC.78,79 Weiss et al., (2003) reported that combinatory
treatment resulted in signicantly increased cell death and
DNA damage for BxPC-3 PDAC cell lines, 24 h post treatment
in a 2D system.79 Similarly, Mukubou et al., (2010) carried out
both in vitro (2D) and in vivo (mouse model) combinatorial
chemo-radiotherapy treatment involving GEM and radiation.78
A dose dependent increase in apoptosis for the combinatorial
treatment regime along with increased cell death was observed
in vitro, 7 day post-treatment (GEM concentrations of 0, 65 and41660 | RSC Adv., 2019, 9, 41649–41663135 nM with radiation between 0–8 Gy). In vivo, they observed
a decreased tumour volume for a combinatorial treatment
(GEM ¼ 300 mg per kg per week and single dose of 5 Gy
radiation) in comparison to chemotherapy or radiotherapy
alone, 40 days post treatment.
In this work, as described in Sections 2.3.3 and 3.3 above, we
performed a chemo-radiotherapy regime with 10 mMGEM and 6
Gy radiation and performed short (24 h, Fig. 5) and relatively
long term (17 days, Fig. 6) analysis of the treatment response.
Similarly to reported animal studies,78 in vitro studies78,79 and
clinical studies,82,105,106 for both short and long post-treatment
time points of analysis, our results show a signicantly lower
viability and higher apoptosis in our scaﬀolds as compared to
the individual/independent treatment regimes.
It should be stated that all reported in vitro studies have
a diﬀerent time-regime, i.e., our long-term study is more aligned
with the time-frame of animal experiments2,11,14,17,23,55,78,79,95
(Fig. 7) and clinical trials,56,58,69,73,105,106 pointing to the great
potential of our scaﬀold in providing a reproducible, low cost
powerful tool for replacing animals in long-term realistic
treatment screening for PDAC.5. Conclusions
Overall, in this work we performed treatment screening, i.e.,
chemotherapy, radiotherapy and a combination of the two, on
our recently published scaﬀold based PDAC model.7 We were
able to capture short (24 h) and long-term (17 days) post-
treatment responses of (i) the chemotherapeutic drug Gemci-
tabine and (ii) radiation (X-rays) on the viability reduction and
apoptosis induction in the scaﬀolds. We observed a change of
the impact of the treatment depending on the time-frame,
especially for radiation for which the PDAC scaﬀolds were
resistant 24 h post-treatment but responded much more aer
17 days post-treatment. It should be stated that, to the best of
our knowledge, we are the rst to report a viable PDAC culture
in a scaﬀold for more than 2 months (without the need of
resuspension) and the rst to perform relatively long-term (17
days) post-treatment observations in vitro. The latter is
particularly important as this time-frame is much closer to
animal studies and to the patient time-frame treatment
regimes, highlighting that our scaﬀold system has great
potential to be used as a good animal free model for screening
of PDAC treatments including treatment personalisation.
Current work of our group focuses on the incorporation of (i)
biological complexity (co-culture of multiple cell types) and (ii)
perfusion/interstitial ow mimicry in the PDAC model for
a better recapitulation of the in vivo niche. Future work will
focus on treatment screening in PDAC models of higher
complexity, to capture more accurately the impact of multiple
compartments of the tumour tissue on the response and
potential resistance to treatment.Conﬂicts of interest
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